首页> 外文期刊>The Journal of Urology >Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
【24h】

Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.

机译:血清肿瘤标志物可预测临床上局限性浸润性膀胱癌患者的总体生存率和疾病特异性生存率。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: We assessed the value of increased levels of carcinoembryonic antigen, CA (cancer antigen) 125 and CA (carbohydrate antigen) 19-9 in predicting the survival of patients with clinically organ confined bladder cancer. MATERIALS AND METHODS: Serum levels of carcinoembryonic antigen, CA 125 and CA 19-9 were measured prospectively in all patients scheduled for cystectomy for clinically organ confined bladder cancer between September 1999 and May 2004. The association between marker levels and overall and disease specific survival rates was assessed, and multivariate analysis was performed to determine the predictive value for outcome. RESULTS: The study included 91 patients with a median followup of 33.5 months (range 3 to 85). Overall and disease specific 5-year survival rates were 47% and 66%, respectively. On univariate analysis CA 19-9 and CA 125 were found to be statistically significant predictors (p <0.001) of overall survival. Respective 1, 2 and 5-year rates were CA 19-9 increased in 65%, 35% and 14%, normal in 83%, 70% and 53%, and CA 125 increased in 50%, 33% and 8%, and normal in 85%, 70% and 55%. CA 19-9 was also a statistically significant predictor (p <0.001) of disease specific survival, with 1, 2 and 5-year rates of 70%, 35% and 24% in patients with high levels vs 89%, 86% and 73% in patients with normal levels. On multivariate Cox regression analysis CA 19-9 (OR 1.5, 95% CI 1.1-2.3, p = 0.02) was an independent predictor of disease specific survival. CONCLUSIONS: Increased CA 19-9 and/or CA 125 levels before cystectomy in patients with clinically organ confined muscle invasive bladder cancer are associated with poor outcome. CA 19-9 appears to be an independent predictor of disease specific mortality. Further larger scale studies are needed to confirm these results.
机译:目的:我们评估了癌胚抗原,CA(癌症抗原)125和CA(碳水化合物抗原)19-9水平的增加在预测临床上器官受限的膀胱癌患者的生存中的价值。材料与方法:前瞻性测量了1999年9月至2004年5月间所有计划行膀胱切除术的临床器官狭窄膀胱癌患者的癌胚抗原,CA 125和CA 19-9的水平。标志物水平与总体和疾病特异性生存之间的关系评估比率,并进行多元分析以确定结果的预测值。结果:该研究纳入91例患者,中位随访时间为33.5个月(范围3至85)。总体和特定疾病的5年生存率分别为47%和66%。在单因素分析中,发现CA 19-9和CA 125是总体存活率的统计学显着预测因子(p <0.001)。 1年,2年和5年率分别为CA 19-9的65%,35%和14%,正常的83%,70%和53%,CA 125的50%,33%和8%,正常的比例为85%,70%和55%。 CA 19-9还是疾病特异性存活率的统计学显着预测指标(p <0.001),高水平患者的1年,2年和5年率分别为70%,35%和24%,而89%,86%和5正常水平的患者为73%。在多因素Cox回归分析中,CA 19-9(OR 1.5,95%CI 1.1-2.3,p = 0.02)是疾病特异性存活率的独立预测因子。结论:在临床上器官受限的肌肉浸润性膀胱癌患者中,进行膀胱切除术前,CA 19-9和/或CA 125的水平升高与预后不良有关。 CA 19-9似乎是疾病特异性死亡率的独立预测因子。需要进一步的大规模研究来证实这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号